Federal Register / Vol. 60, No. 235 / Thursday, December 7, 1995 / Notices 62883

of the reproduction fee of $2.75 per

copy.

Dated: November 30, 1995.

Stephen G. Kopach,

Chief Cadastral Surveyor.

[FR Doc. 95–29853 Filed 12–6–95; 8:45 am]

BILLING CODE 4310–GJ–M

[WY–923–1430–01; WYW 134662]

Notice of Proposed Withdrawal and

Opportunity for Public Meeting;

Wyoming

AGENCY: Bureau of Land Management,

Interior.

ACTION: Notice.

SUMMARY: The Bureau of Land

Management proposed to withdraw

1,020 acres of public land in Fremont

County, to protect the habitat of the

small rockcress, Aravis pusilla. This

notice closes the land for up to 2 years

from surface entry and mining. The land

will remain open to mineral leasing.

DATE: Comments and requests for

meeting should be received on or before

March 6, 1995.

ADDRESS: Comments and meeting

requests should be sent to the Wyoming

State Director, BLM, P.O. Box 1828,

Cheyenne, Wyoming 82003–1828.

FOR FURTHER INFORMATION CONTACT:

Janet Booth, BLM Wyoming State Office,

(307) 775–6124.

SUPPLEMENTARY INFORMATION: On

November 8, 1995, a petition was

approved allowing the Bureau of Land

Management to file an application to

withdraw the following described

public land from settlement, sale,

location, or entry under the general land

laws, including the mining laws, subject

to valid existing rights:

Sixth Principal Meridian

T. 29 N., R. 101 W.,

Sec. 26, S1⁄2NW1⁄4, S1⁄2;

Sec. 27, E1⁄2SW1⁄4NE1⁄4, SE1⁄4NE1⁄4,

E1⁄2W1⁄2SE1⁄4, E1⁄2SE1⁄4;

Sec. 35, N1⁄2, N1⁄2N1⁄2SW1⁄4, N1⁄2SE1⁄4.

The area described contains approximately

1,020 acres in Fremont County.

The purpose of the proposed

withdrawal is to protect the habitat of

the small rockcress, Arabis pusilla, a

plant species proposed as Threatened

and Endangered by the U.S. Fish and

Wildlife Service. The Pine Creek area at

South Pass is the only known location

for this species in the world.

For a period of 90 days from the date

of publication of this notice, all persons

who wish to submit comments,

suggestions, or objections in connection

with the proposed withdrawal may

present their views in writing to the

undersigned officer of the Bureau of

Land Management.

Notice is hereby given that an

opportunity for a public meeting is

afforded in connection with the

proposed withdrawal. All interested

persons who desire a public meeting for

the purpose of being heard on the

proposed withdrawal must submit a

written request to the Wyoming State

Director within 90 days from the date of

publication of this notice. Upon

determination by the authorized officer

that a public meeting will be held, a

notice of time and place will be

published in the Federal Register, at

least 30 days before the scheduled date

of the meeting.

The application will be processed in

accordance with the regulations set

forth in 43 CFR 2300.

For a period of 2 years from the date

of publication of this notice in the

Federal Register, the land will be

segregated as specified above unless the

application is denied or canceled or the

withdrawal is approved prior to that

date. Licenses, permits, cooperative

agreements, or discretionary land use

authorizations of a temporary nature

which would not impact the plant

habitat may be allowed with the

approval of an authorized officer of the

Bureau of Land Management during the

segregative period.

Alan K. Kesterke,

Associate State Director.

[FR Doc. 95–29861 Filed 12–6–95; 8:45 am]

BILLING CODE 4310–22–M

Minerals Management Service

Outer Continental Shelf, Western Gulf

of Mexico, Oil and Gas Lease Sale

155—Extension

AGENCY: Minerals Management Service,

Interior.

ACTION: Notice to extend post-sale

evaluation period for Western Gulf of

Mexico Lease Sale 155.

SUMMARY: The furlough of workers of

the Minerals Management Service

(MMS) delayed the evaluation of bids

from Lease Sale 155 in the Western Gulf

of Mexico. This notice extends by 9

days the post-sale evaluation period for

Western Gulf of Mexico Lease Sale 155.

The extra time will allow MMS

personnel to properly evaluate bids.

DATES: The post-sale evaluation period

ends on December 20, 1995.

FOR FURTHER INFORMATION CONTACT:

John Mirabella or Kumkum Ray,

Engineering and Standards Branch,

telephone (703) 787–1600.

SUPPLEMENTARY INFORMATION: On August

11, 1995, MMS published a lease sale

notice in the Federal Register (60 FR

41105) announcing a lease sale in the

Western Gulf of Mexico with bid

openings on September 13, 1995. On

November 14, 1995, during the

evaluation of the bids received from the

lease sale, MMS experienced a 6-day

shutdown of all but essential work of

the agency. This shutdown broke the

continuity of the work of evaluating

bids and delayed the evaluation process.

MMS is extending the evaluation period

to allow personnel to properly evaluate

the bids received. MMS will complete

the evaluation of all bids received for

this sale by December 20, 1995.

Dated: December 4, 1995.

Thomas M. Gernhofer,

Associate Director for Offshore Minerals

Management.

[FR Doc. 95–29839 Filed 12–6–95; 8:45 am]

BILLING CODE 4310–MR–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled

Substances; Notice of Registration

By Notice dated May 31, 1995, and

published in the Federal Register on

June 8, 1995, (60 FR 30318), Radian

Corporation, P.O. Box 201088, 8501

Mopac Blvd., Austin, Texas 78720,

made application to the Drug

Enforcement Administration (DEA) to

be registered as a bulk manufacturer of

the basic classes of controlled

substances listed below:

Schedule

Drug:

Cathinone (1235) ......................... I

.

Methcathinone (1237) I

N-Ethylamphetamine (1475) ........ I

N,N-Dimethylamphetamine

(1480).

I

Aminorex (1585) .......................... I

4-Methylaminorex (cis isomer)

(1590).

I

Methaqualone (2565) .................. I

Lysergic acid diethylamide (7315) I

Tetrahydrocannabinols (7370) ..... I

Mescaline (7381) ......................... I

3,4-Methylenedioxyamphetamine

(7400).

I

3,4-Methylenedioxy-Nethylamphetamine (7404).I

3,4-

Methylenedioxymethamphetamine (7405).

I

4-Methoxyamphetamine (7411) ... I

Psilocybin (7437) ......................... I

Psilocyn (7438) ............................ I

Dihydromorphine (9145) .............. I
62884 Federal Register / Vol. 60, No. 235 / Thursday, December 7, 1995 / Notices

Schedule

Normorphine (9313) ..................... I

Acetylmethadol (9601) ................. I

Alphacetylmethadol except LevoAlphacetylmethadol (9603).I

Normethadone (9635) ................. I

3-Methylfentanyl (9813) ............... I

Amphetamine (1100) ................... II

Methamphetamine (1105) ........... II

Methylphenidate (1724) ............... II

Amobarbital (2125) ...................... II

Pentobarbital (2270) .................... II

Secobarbital (2315) ..................... II

Phencyclidine (7471) ................... II

1-Piperidinocyclohexane- ............

carbonitrile (8603) ........................

II

Dihydrocodeine (9120) ................ II

Oxycodone (9143) ....................... II

Hydromorphone (9150) ................ II

Diphenoxylate (9170) .................. II

Benzoylecgonine (9180) .............. II

Ethylmorphine (9190) .................. II

Hydrocodone (9193) .................... II

Isomethadone (9226) .................. II

Meperidine (9230) ....................... II

Methadone (9250) ....................... II

Methadone-intermediate (9254) .. II

Morphine (9300) .......................... II

Levo-alphacetylmethadol (9648) . II

Oxymorphone (9652) ................... II

Alfentanil (9737) .......................... II

Sufentanil (9740) ......................... II

Fentanyl (9801) ........................... II

A registered manufacturer filed a

request for a hearing with respect to

amphetamine and methamphetamine.

The requesting party subsequently

submitted a letter dated August 29,

1995, withdrawing their request for a

hearing. On September 1, 1995, an order

terminating the proceedings was issued

by Administrative Law Judge Mary

Ellen Bittner. Another registered

manufacturer filed a comment

requesting that the firm’s application to

manufacture meperidine be denied

because there is no need for Radian to

register as a third domestic

manufacturer of meperidine and that

Radian must show it can maintain

adequate safeguards against the theft

and diversion of meperidine. In regards

to this comment, the firm, which has

been approved as a manufacturer of

meperidine for previous applications,

has been subject to periodic in-depth

investigations by DEA to evaluate the

firm’s fitness as a DEA registrant.

Additionally, in response to this recent

application, the firm was inspected by

DEA and found to have adequate

safeguards to prevent the theft or

diversion of meperidine. Therefore,

pursuant to Section 303 of the

Comprehensive Drug Abuse Prevention

and Control Act of 1970 and Title 21,

Code of Federal Regulations, Section

1301.54(e), the Deputy Assistant

Administrator, Office of Diversion

Control, hereby orders that the

application submitted by the above firm

for registration as a bulk manufacturer

of the basic classes of controlled

substances listed above is granted.

Dated: November 29, 1995.

Gene R. Haislip,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 95–29772 Filed 12–6–95; 8:45 am]

BILLING CODE 4410–09–M

[Docket No. 94–23]

Prince George Daniels, D.D.S.; Denial

of Application

On January 31, 1994, the Deputy

Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration (DEA), issued an Order

to Show Cause to Prince George Daniels,

D.D.S., (Respondent) of San Jose,

California, notifying him of an

opportunity to show cause as to why

DEA should not deny his pending

application under 21 U.S.C. 823(f), as

being inconsistent with the public

interest. Specifically, the Order to Show

Cause alleged that:

(1) Between December 2, 1982 and

February 3, 1983, [the Respondent]

issued four prescriptions for Didrex, a

Schedule III controlled substance, to

two undercover individuals[,] and these

prescriptions were not issued for a

legitimate medical purpose in the usual

course of [his] professional practice.

(2) On June 7, 1983, in the Municipal

Court, Santa Clara County Judicial

Circuit, State of California, [the

Respondent] pled no contest to two

counts of prescribing controlled

substances to a person not under [his]

treatment for a pathology in violation of

California Health and Safety Code

[Section] 11154 and one count of

practicing unauthorized medicine in

violation of California Business and

Professions Code [Section] 2052.

(3) On January 7, 1985, the Board of

Dental Examiners, Department of

Consumer Affairs, State of California

(Dental Board), suspended [the

Respondent’s] state dental license for

one year, but stayed this suspension

pending the successful completion of

three years probation.

(4) On or about May 1, 1986, [the

Respondent] arranged for the sale of

cocaine to an undercover DEA agent.

Furthermore, [he] made arrangements

for other individuals to forcibly take the

cocaine from the DEA undercover agent

after [he] sold him the cocaine.

(5) On January 3, 1987 [the

Respondent’s] previous DEA number,

AD6665838, expired [,] and [he] did not

submit a renewal application for that

number. Thereafter [his] DEA number

was retired from DEA registration.

(6) On August 14, 1987, in the United

States District Court, District of

Northern California, [the Respondent]

pled guilty to one count of conspiracy

to deliver cocaine in violation of 21

U.S.C. 841 and 846 and to one count of

possession of cocaine in violation of 21

U.S.C. 841. On October 2, 1987, [the

Respondent was] sentenced to three

years imprisonment.

(7) On August 22, 1988, the Dental

Board terminated [the Respondent’s]

probation and revoked [his] state dental

license. Effective January 10, 1990, the

Dental Board restored [his] state dental

license but placed [his] license on a

three year probationary term.

On March 9, 1994, the Respondent

filed a timely request for a hearing, and

following prehearing procedures, a

hearing was held in San Francisco,

California, on November 9, 1994, before

Administrative Law Judge Paul A.

Tenney. At the hearing, the Government

offered the stipulated testimony of two

witnesses and introduced various

documentary exhibits, and the

Respondent, represented by counsel,

testified, called three witnesses, and

introduced several documentary

exhibits. After the hearing, counsel for

both sides submitted proposed findings

of fact, conclusions of law and

argument. On January 30, 1995, Judge

Tenney issued his Findings of Fact,

Conclusions of Law, and Recommended

Ruling, recommending that the

Respondent’s application for a DEA

Certificate of Registration be denied.

Neither party filed exceptions to his

decision, and on March 9, 1995, Judge

Tenney transmitted the record of these

proceedings to the Deputy

Administrator.

The Deputy Administrator has

considered the record in its entirety,

and pursuant to 21 CFR 1316.67, hereby

issues his final order based upon

findings of fact and conclusions of law

as hereinafter set forth. The Deputy

Administrator adopts, in full, the

opinion and recommended ruling of the

Administrative Law Judge, and his

adoption is in no manner diminished by

any recitation of facts, issues and

conclusions herein, or of any failure to

mention a matter of fact or law.

The Deputy Administrator finds that

the Respondent received his license to

practice dentistry in California in 1975.

Further, the Respondent previously held

a DEA Certificate of Registration,

AD6665838, which expired on June 30,

1986, and which the Respondent did

not renew but let lapse. However, on

November 12, 1992, the Respondent